Thomas Ebensen

Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model.

The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties.

The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.

A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties.

Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.

Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.

The toll-like receptor 2/6 ligand MALP-2 reduces the viability of Mycobacterium tuberculosis in murine macrophages.

Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.

The member of the cyclic di-nucleotide family bis-(3', 5')-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant.

Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.

Development and characterization of attenuated metabolic mutants of Bordetella bronchiseptica for applications in vaccinology.

Vaccine adjuvants: key tools for innovative vaccine design.

Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties.

A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.

Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.

Pegylated bisacycloxypropylcysteine, a diacylated lipopeptide ligand of TLR6, plays a host-protective role against experimental Leishmania major infection.

Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation.

Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination.

Modeling Influenza Virus Infection: A Roadmap for Influenza Research.

New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.

Self-Replicating RNA Vaccine Delivery to Dendritic Cells.

Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi.

Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver.

Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation Pathway.

Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.

Self-replicating RNA vaccine functionality modulated by fine-tuning of polyplex delivery vehicle structure.

Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice.

Dual dye in-vivo imaging of differentially charged PLGA carriers reveals antigen-depot effect, leading to improved immune responses in preclinical models.

Influenza-Activated ILC1s Contribute to Antiviral Immunity Partially Influenced by Differential GITR Expression.

Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids.

The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization.

Novel colloidal associations of soyasaponins and lipid components (DPPC, cholesterol) as potential adjuvants for vaccines.

The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.

Invariant NKT Cell-Mediated Modulation of ILC1s as a Tool for Mucosal Immune Intervention.

Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine.

Mucosal CD8+ T cell responses induced by an MCMV based vaccine vector confer protection against influenza challenge.

Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against .